The registration marks a strategic pivot for the Israel-based company, moving its technology beyond pregnancy monitoring into the wider women’s health sector. By enabling patients to perform their own follicular and endometrial scans, the system aims to reduce the logistical burden of repeated clinic visits during IVF and fertility preservation treatments.

Data from the Human Fertilisation and Embryology Authority underscores the scale of the local opportunity, noting that 53,000 patients underwent IVF in 2024, resulting in 21,400 births. CEO Elazar Sonnenschein stated that the goal is to reverse the current care model, which often requires patients to structure their daily lives around clinical monitoring schedules. Following its recent European certification, the company plans to target additional markets with high volumes of fertility treatment cycles to solidify its footprint in remote care.